Moderna and Merck announced Wednesday that a personalized mRNA vaccine combined with immunotherapy reduced the recurrence and spread of melanoma [1], [2].
The results represent a potential shift in treating one of the deadliest forms of skin cancer. By using mRNA technology to create a vaccine tailored to an individual's specific tumor, doctors may be able to prevent cancer from returning after initial treatment [1], [2].
The late-stage trial tested the personalized mRNA vaccine in conjunction with Keytruda, an immunotherapy drug developed by Merck [1], [3]. The combination therapy aimed to prime the immune system to recognize and attack remaining cancer cells more effectively than standard care [2], [4].
Market reaction to the announcement was immediate and volatile. Moderna shares rose significantly on Wednesday, though reports on the exact increase varied by source. Forbes and Channel 4 News reported the stock rocketed by 93 percent [1], [4], while MSN U.S. reported an 84 percent increase [3]. Another report from MSN India cited a jump as high as 135 percent [5].
Tyler Roush of Forbes said, "Shares of Moderna rocketed by 93% to around $121.90 on Wednesday, pacing what would be the stock's best‑ever trading session" [4].
While the companies focused on the clinical outcomes, financial analysts are already projecting the long-term commercial impact of the therapy. Some analysts forecast that the vaccine could generate $3 billion in annual sales by 2035 [3].
The trial results, described by some as interim and others as late-stage, mark a landmark moment for the application of mRNA technology beyond infectious diseases [2], [3]. This approach uses the same genetic sequencing technology that powered the rapid development of COVID-19 vaccines to target oncology [1].
“A personalized mRNA vaccine combined with immunotherapy reduced the recurrence and spread of melanoma.”
This development signals a transition for mRNA technology from a tool for pandemic response to a viable platform for personalized oncology. If these results hold through regulatory approval, it validates the 'personalized medicine' model, where treatments are manufactured based on a patient's unique genetic profile rather than a one-size-fits-all drug.
